← Steven E. Nissen

Papers by Steven E. Nissen

Page 1 · newest first

1. Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV)American Heart Journal · 2016
2. Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a)New England Journal of Medicine · 2026
3. Extended Analyses of Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a)NEJM Evidence · 2026
4. Office blood pressure changes during tonlamarsen run-in versus placebo lead-in the KARDINAL phase 2 trial: a post-hoc analysisAmerican Journal of Preventive Cardiology · 2026
5. Bariatric Surgery as a Rescue Strategy After Semaglutide or TirzepatideAnnals of Surgery · 2026
6. Highlights of the Year in JACC 2011Journal of the American College of Cardiology · 2012
7. Outcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysisEuropean Journal of Preventive Cardiology · 2026
8. Bempedoic Acid and Incidence of Stroke Among Statin-Intolerant Patients: An Analysis of the Clear Outcomes TrialAtherosclerosis · 2026
9. Factors Associated With Enhanced LDL-Cholesterol Lowering With Bempedoic Acid Among Statin-Intolerant Patients From Clear OutcomesAtherosclerosis · 2026
10. Bempedoic Acid Without Background Llt, LDL Cholesterol and Cardiovascular Events: A Secondary Analysis of the Clear Outcomes TrialAtherosclerosis · 2026
11. The Association Between Bempedoic Acid and Risk of Venous Thromboembolism: A Post Hoc Analysis of the Clear Outcomes TrialAtherosclerosis · 2026
12. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trialsThe Lancet · 2023
13. Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trialNature Medicine · 2026
14. Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trialThe Lancet · 2025
15. Relationship Between Biomarkers of Oxidized Low-Density Lipoprotein, Statin Therapy, Quantitative Coronary Angiography, and Atheroma VolumeJournal of the American College of Cardiology · 2008
16. Sex Differences in Coronary Atheroma Regression After Intensive Lipid-Lowering TherapyJACC Advances · 2026
17. Safety and lipoprotein(a)-lowering effects of Kylo-11, a non-canonical, long-duration small interfering RNA targeting lipoprotein(a): a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trialThe Lancet · 2026
18. Echocardiographic Changes With Mavacamten in Nonobstructive Hypertrophic CardiomyopathyJournal of the American College of Cardiology · 2025
19. Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic CardiomyopathyJournal of the American College of Cardiology · 2025
20. Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310New England Journal of Medicine · 2026
21. Coronary reactivity to nitroglycerin: Intravascular ultrasound evidence for the importance of plaque distributionJournal of the American College of Cardiology · 1995
22. Bempedoic Acid and First and Recurrent Limb Outcomes in Statin-Intolerant Patients With Peripheral Artery Disease: Insights From the CLEAR Outcomes TrialCirculation · 2026
23. Mavacamten in Obstructive Hypertrophic Cardiomyopathy Patients Referred for Septal ReductionJournal of the American College of Cardiology · 2024
24. Effect on Lipoprotein(a) Oxidized Phospholipids of Lepodisiran, an Extended-Duration siRNA Targeting Lipoprotein(a)Journal of the American College of Cardiology · 2026
25. 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical TrialsCirculation · 2014
26. American College of Cardiology clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound studies (ivus)31When citing this document, the American College of Cardiology would appreciate the following citation format: Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ, Pinto FJ, Rosenfield K, Siegel RJ, Tuzcu EM, Yock PG. ACC Clinical Expert Consensus Document on Standards for the acquisition, measurement and reporting of intravascular ultrasound studies: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents (Committee to Develop a Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies [IVUS]). J Am Coll Cardiol2001;37:1478–92.33Address for reprints: This document is available on the ACC Website at www.acc.org. Reprints of this document are available for $5.00 each by calling 800-253-4636 (U.S. only) or writing to the Resource Center, American College of Cardiology, Educational Services, 9111 Old Georgetown Road, Bethesda, MD 20814-1699.Journal of the American College of Cardiology · 2001
27. Efficacy and Safety of Bempedoic Acid in Patients Aged ≥75 Years Stratified by Varying Statin Exposure: Results From Phase 3 Studies of Bempedoic AcidJournal of the American Heart Association · 2026
28. Adverse Cardiovascular Outcomes in Patients With Obstructive Sleep Apnea and ObesityJournal of the American College of Cardiology · 2024
29. Intravascular Ultrasound Evidence of Angiographically Silent Progression in Coronary Atherosclerosis Predicts Long-Term Morbidity and Mortality After Cardiac TransplantationJournal of the American College of Cardiology · 2005
30. 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical TrialsJournal of the American College of Cardiology · 2014
31. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical TrialsENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2018
32. Long-Term Cardiovascular Outcomes After Bariatric Surgery in the Medicare PopulationJournal of the American College of Cardiology · 2022
33. Technology-Assisted Self-Selection of Candidates for Nonprescription Statin TherapyJournal of the American College of Cardiology · 2021
34. Inaccurate information regarding cardiovascular disease prevention enabled by generative artificial intelligenceAmerican Journal of Preventive Cardiology · 2026
35. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 DiabetesNew England Journal of Medicine · 2025
36. Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3New England Journal of Medicine · 2025
37. Mavacamten in Symptomatic Nonobstructive Hypertrophic CardiomyopathyNew England Journal of Medicine · 2025
38. From LDL-C to lipoprotein(a) - those who fail to learn from history are doomed to repeat itAmerican Journal of Preventive Cardiology · 2025
39. Multiplicity Control in Clinical TrialsNEJM Evidence · 2025
40. Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT ‐ MMO trialObesity · 2025
41. Differential cardiovascular impact of ω-3 fatty acid in patients at high cardiovascular risk in Asians versus non-Asians: Sub-analysis of the strength randomized clinical trialAtherosclerosis · 2025
42. Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular RiskNew England Journal of Medicine · 2025
43. Lorundrostat Efficacy and Safety in Patients with Uncontrolled HypertensionNew England Journal of Medicine · 2025
44. Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)New England Journal of Medicine · 2025
45. Achieved levels of apolipoprotein B and plaque composition after acute coronary syndromes: Insights from HUYGENSAtherosclerosis · 2025
46. Bempedoic Acid for Prevention of Cardiovascular Events in People With Obesity: A CLEAR Outcomes Subset AnalysisJournal of the American Heart Association · 2025
47. Expanding the triglyceride range in clinical trials: therapeutic opportunitiesEuropean Heart Journal · 2025
48. Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a)JAMA · 2024
49. Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCMCirculation · 2024
50. Mavacamten-Associated Temporal Changes in Left Atrial Function in Obstructive HCMJACC. Cardiovascular imaging · 2024